Bio-Rad Laboratories (BIO) has been receiving both bullish and bearish predictions from financial analysts. The company's stocks went through multiple fluctuations and touched a 52-week low at different instances due to various market shifts. Jefferies recently cut Bio-Rad's target to $285, maintaining a hold. The company's shares have also slid 28% as some confidence is lacking in Bio-Rad's performance. Despite missing Q4 earnings and revenue estimates, Ariel Fund considers Bio-Rad a classic stock. Although some optimistically consider $331 a great opportunity to watch Bio-Rad, others tend to opine that the company might be overvalued. Amid these circumstances, a top executive at Bio-Rad has made a major stock sale. Several bullish analysts believe that Bio-Rad has a healthy balance sheet and is generally undervalued. The company, however, faced a significant fallout when it reported a $1.8 billion loss prompting layoffs. An SWOT analysis reveals a mixed outlook for the company's stock. Through all these market challenges, Bio-Rad still manages to satisfy some investors, surpassing Q3 estimates and witnessing an increase in stock aftermarket. A future acquisition of Stilla Technologies is also under speculation.
Bio-Rad Laboratories Stocks News Analytics from Mon, 09 Nov 2015 08:00:00 GMT to Fri, 28 Mar 2025 10:20:47 GMT -
